NEW YORK, NY / ACCESSWIRE / April 24, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Aarons, Inc. (AAN)
Investors Affected : March 2, 2018 - February 19, 2020
A class action has commenced on behalf of certain shareholders in Aarons, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Aaron's had inadequate disclosure controls, procedures, and compliance measures; (ii) consequently, the operations of Aaron's Progressive Leasing ("Progressive") and Aaron's Business ("AB") segments were in violation of the Federal Trade Commission ("FTC") Act and/or relevant FTC regulations; (iii) consequently, Aaron's earnings from those segments were partially derived from unlawful business practices and were thus unsustainable; (iv) the full extent of Aaron's liability regarding the FTC's investigation into its Progressive and AB segments, Aaron's noncompliance with the FTC Act, and the likely negative consequences of all the foregoing on the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/aarons-inc-loss-submission-form/?id=6169&from=1
AnaptysBio, Inc. (ANAB)
Investors Affected : October 10, 2017 - November 7, 2019
A class action has commenced on behalf of certain shareholders in AnaptysBio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/anaptysbio-inc-loss-submission-form/?id=6169&from=1
Zoom Video Communications, Inc. (ZM)
Investors Affected : April 18, 2019 - April 6, 2020
A class action has commenced on behalf of certain shareholders in Zoom Video Communications, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Zoom had inadequate data privacy and security measures; (ii) contrary to Zoom's assertions, the Company's video communications service was not end-to-end encrypted; (iii) as a result of all the foregoing, users of Zoom's communications services were at an increased risk of having their personal information accessed by unauthorized parties, including Facebook; (iv) usage of the Company's video communications services was foreseeably likely to decline when the foregoing facts came to light; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/zoom-video-communications-inc-loss-submission-form/?id=6169&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com: